Research Topics
| Angeline BartholomeuszSummaryAffiliation: Royal Melbourne Hospital Country: Australia Publications
| Collaborators
|
Detail Information
Publications
HBV drug resistance: mechanisms, detection and interpretationTim Shaw
Victorian Infectious Diseases Reference Laboratory, Locked Bag 815, Carlton South, Vic. 3053, Australia
J Hepatol 44:593-606. 2006- Hepatitis B virus mutations associated with antiviral therapyA Bartholomeusz
Victorian Infectious Disease Reference Laboratory, North Melbourne, Australia
J Med Virol 78:S52-5. 2006..Clearly, improved treatment strategies are required urgently to prevent the continued selection of HBV drug-resistant mutants... - Comparisons of the HBV and HIV polymerase, and antiviral resistance mutationsAngeline Bartholomeusz
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
Antivir Ther 9:149-60. 2004..In addition, the antiviral resistance mutations including potential compensatory mutations were mapped to determine their effect on the HBV polymerase model, especially in the nucleotide binding site... - Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individualsPeter A Revill
Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
AIDS 21:1701-10. 2007..To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy... 
The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitroNadia Warner
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
Antimicrob Agents Chemother 51:2285-92. 2007....- Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failureAnna Ayres
Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, Melbourne, Victoria, 3051, Australia
J Clin Virol 27:111-6. 2003..CONCLUSIONS: Monitoring for the accumulation of unique mutations within the genome of drug resistant HBV mutants isolated during long term antiviral therapy appears warranted in the clinical management of patients with CHB... - Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individualsLouise Cooley
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
AIDS 17:1649-57. 2003..These patients exhibited significantly elevated HBV viral loads and serum ALT, and three were infected with a lamivudine-resistant HBV strain that was potentially transmissible to HBV-vaccinated individuals... - SeqHepB: a sequence analysis program and relational database system for chronic hepatitis BLilly K W Yuen
Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, 3051 Vic, Australia
Antiviral Res 75:64-74. 2007.... - Antiviral drug resistance: clinical consequences and molecular aspectsAngeline Bartholomeusz
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
Semin Liver Dis 26:162-70. 2006.... - Hepatitis B virus genotypes: comparison of genotyping methodsAngeline Bartholomeusz
Victorian Infectious Diseases Reference Laboratory, North Melbourne 3051, Australia
Rev Med Virol 14:3-16. 2004..A numbering system is presented which avoids this problem. In addition we discuss the currently available methods for genotyping HBV... - Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factorsAlexander J V Thompson
St Vincent s Hospital, Melbourne, Victoria, Australia
J Gastroenterol Hepatol 22:1078-85. 2007..The present study was designed to identify factors predictive of lamivudine resistance, with a particular focus on the role of precore and basal core promoter variants in the setting of hepatitis B e antigen-negative disease... - HBV genotyping and analysis for unique mutationsAnna Ayres
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
Methods Mol Med 95:125-49. 2004 - Lamivudine resistant occult HBV: implications for public health?Scott Bowden
Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Vic 3051, Australia
J Hepatol 38:526-8. 2003 
Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabodyRenae Walsh
Victorian Infectious Diseases Reference Laboratories, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
Virology 411:132-41. 2011..In vitro data from HBV/precore hepatocyte cell lines demonstrated effective intrabody regulation of precore/HBeAg...- The hepatitis B virus and common mutantsStephen Locarnini
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
Semin Liver Dis 23:5-20. 2003..Such research should help improve the basic understanding of this unique virus-host relationship and provide new strategies for complete control of HBV infections... - Evolving therapies for the treatment of chronic hepatitis B virus infectionWilliam Delaney
Victorian Infectious Diseases Reference Laboratory, Carlton South, VIC 3053, Australia
Expert Opin Investig Drugs 11:169-87. 2002.... - Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovirJulie Sheldon
Hospital Carlos Ill, Madrid, Spain
Antivir Ther 10:727-34. 2005..In vitro, rtA194T conferred a reduced susceptibility to TDF in the presence of LAM-associated mutations... - A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeuticsChristopher P Desmond
Department of Gastroenterology, Alfred Hospital, Melbourne, Australia
Antivir Ther 13:161-75. 2008..The immune response to hepatitis B virus (HBV) is important for both viral control and disease pathogenesis. A detailed understanding of the HBV-specific T-cell responses may potentially lead to novel therapeutic strategies for HBV... - Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virusJoseph J Y Sung
Department of Medicine and Therapeutics, 9 F Prince of Wales Hospital, The Chinese University of Hong Kong, NT, Shatin, Hong Kong
J Virol 82:3604-11. 2008..Different HBV genotypes may have different virologic mechanisms of hepatocarcinogenesis... - Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activityJulie Sheldon
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
J Acquir Immune Defic Syndr 46:279-82. 2007..Given the overlap between envelope and polymerase in the hepatitis B virus (HBV) genome, changes in antigenic sites of the HBV surface antigen may occur as a result of selection of drug-resistance mutations... - Advances in hepatitis C: what is coming in the next 5 years?Stephen A Locarnini
Victorian Infectious Diseases Reference Laboratory VIDRL, Melbourne, LB 815, Carlton South, Victoria 3053, Australia
J Gastroenterol Hepatol 17:442-7. 2002..Current developments in antiviral agents are reviewed in the context of these potential new viral targets for the future treatment of HCV in chronically infected individuals... - Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantationGeorge K K Lau
Division of Gastroenterology and Hepatology, University of Hong Kong, Hong Kong Special Administrative Region, China
Hepatology 36:702-9. 2002..09; P =.021). In conclusion, preemptive lamivudine reduced HBV exacerbation. The use of lamivudine with other immunosuppressive regimens to prevent exacerbation of HBV should be further explored... - Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for managementAnna S Lok
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
Hepatology 46:254-65. 2007..Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy... - Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerasePeter Angus
Austin Hospital, Studley Road, Heidelberg, Victoria 3084, Australia
Gastroenterology 125:292-7. 2003..The aim of this study was to characterize adefovir resistance in a patient who developed clinical and virologic evidence of breakthrough during a 96-week course of treatment... - Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strainsFiona Wightman
Department of Medicine, Monash University, Melbourne, Australia
J Clin Microbiol 42:3809-12. 2004..Excellent concordance was demonstrated between sequencing and the discriminatory real-time assay; however, a mixture of quasispecies was more frequently detected by discriminatory real-time PCR... - Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantationChee-Kin Hui
Division of Gastroenterology and Hepatology, University Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, SAR, China
J Clin Virol 32:173-8. 2005..CONCLUSION: Our findings suggested that sexual precautions should be taken in these patients after HCT. Alternatively, or even additionally, active vaccination should be delivered to these patients once they have lost their HBV immunity... - Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapyJ Judy Chang
Infectious Diseases Unit, Alfred Hospital, Commercial Rd, Melbourne, Victoria 3004, Australia
J Virol 79:3038-51. 2005..Therefore, HIV-1 infection has a significant and specific effect on HBV-specific T-cell immunity... - Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapyGail V Matthews
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
AIDS 20:863-70. 2006..Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy... - Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype CHenry L Y Chan
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People s Republic of China
J Infect Dis 191:2022-32. 2005..We aimed to investigate the characteristics of hepatitis B virus (HBV) genotype C subgroups in Hong Kong and their relationship with HBV genotype C in other parts of Asia... - Transmission of G145R mutant of HBV to an unrelated contactVarsha Thakur
Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India
J Med Virol 76:40-6. 2005..The data also reaffirms the earlier finding of HBsAg positivity in presence of G145R mutation of the S-gene. HBV exists as quasi-species and mixed population in subjects with chronic HBV infection...